New Biomarkers of antitumor T cells asspcoate woth improved prognosis in endometrial cancer

by VHIO

1 year ago
endometrial cancer

The T-cell infiltrate of 47 endometrial tumors has been analyzed with the aim of defining tumor-reactive CD8+ and CD4+ TIL populations that could be very valuable in identifying prognostic and predict...

A therapeutic target for the treatment of endometrial cancer with mutations in the ARID1A gene has been identified

by IRB Lleida. Institut de Recerca Biomèdica

2 years ago
endometrial cancer

Research led by the Oncological Pathology research group at the Institute for Research in Biomedicine of Lleida (IRBLleida), the University of Lleida (UdL) and the Department of Pathological Anatomy o...

A study evaluates the effectiveness of colon and gynecological surgeries and their risk reduction in patients affected by Lynch syndrome

by Hospital Universitari de Bellvitge

3 years ago
Lynch syndrome, cancer, endometrial cancer, colon

he results show that this type of surgery can represent a good option for people affected by this syndrome since it supposes a reduction in the incidence of cancer and its mortality.

Promega Developing OncoMate™ MSI Assay as Companion Diagnostic for Endometrial Cancer Drug Candidate from Incyte

by Promega Biotech Ibérica

4 years ago
retifanlimab, drug, Endometrial Cancer, MSI, OncoMate

Promega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte’s anti-PD-1 drug cand...

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting

by Ability Pharma

5 years ago
clinical trial, oncology drugs, endometrial cancer, lung cancer, ABTL0812

AbilityPharma (Ability Pharmaceuticals, SL) a biopharmaceutical company developing oncology drugs, announced today that the company will release the first results of the currently ongoing phase 1/2...

MIT selects a project to develop a new molecular kit for the diagnosis of endometrial cancer

by Vall d’Hebron

7 years ago
molecular kit, diagnostics, endometrial cancer, MIT, GynEC-DX kit

The Massachusetts Institute of Technology (MIT) through the Foundation for Innovation and the Prospective Health in Spain (FIPSE) has selected, from among hundreds of proposals, the CEMARK project to ...

The Biomedical Research group in Gynecology at VHIR receives a grant from CaixaImpulse

by Vall d’Hebron

7 years ago
CaixaImpulse, endometrial cancer

The group of Biomedical Research in Gynecology of the Vall d'Hebron Research Institute (VHIR), led by Dr. Antonio Gil, has received one of 20 grants from the 2nd edition of CaixaImpulse, awarded by th...

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients

by Ability Pharma

8 years ago
ABTL0812, carboplatin, paclitaxel, cancer, lung, endometrial cancer

ABTL0812 is administered in combination with carboplatin and paclitaxel. Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead...

Ability Pharmaceuticals enters into a licensing agreement with SciClone Pharmaceuticals for the novel anticancer agent ABTL0812 for the China market

by Ability Pharma

8 years ago
PI3K/Akt/mTOR, ABTL0812, lung cancer, endometrial cancer, SciClone Pharmaceuticals

Collaboration boosts development of a fully differentiated inhibitor of the PI3K/Akt/mTOR pathway. ABTL0812 is currently in Phase 2 clinical trials to treat lung and endometrial cancers.